Adicet Bio (NASDAQ:ACET - Get Free Report) posted its earnings results on Wednesday. The company reported ($0.34) EPS for the quarter, meeting analysts' consensus estimates of ($0.34), Yahoo Finance reports.
Adicet Bio Price Performance
Adicet Bio stock traded up $0.02 during trading hours on Thursday, reaching $1.32. The company had a trading volume of 379,773 shares, compared to its average volume of 1,115,965. The firm has a market cap of $108.77 million, a price-to-earnings ratio of -0.51 and a beta of 1.81. The company has a 50-day moving average price of $1.43 and a 200 day moving average price of $1.43. Adicet Bio has a 12-month low of $1.05 and a 12-month high of $3.77.
Analysts Set New Price Targets
Several equities research analysts have issued reports on ACET shares. Guggenheim started coverage on Adicet Bio in a report on Monday, September 30th. They set a "buy" rating and a $7.00 price objective on the stock. Wedbush reaffirmed an "outperform" rating and issued a $5.00 price target on shares of Adicet Bio in a research report on Friday, September 20th. Canaccord Genuity Group cut their price objective on Adicet Bio from $19.00 to $8.00 and set a "buy" rating for the company in a report on Wednesday, September 11th. StockNews.com upgraded Adicet Bio from a "sell" rating to a "hold" rating in a research report on Tuesday, October 8th. Finally, HC Wainwright reissued a "neutral" rating on shares of Adicet Bio in a report on Wednesday, October 16th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, Adicet Bio presently has a consensus rating of "Moderate Buy" and an average price target of $7.50.
Get Our Latest Research Report on Adicet Bio
Adicet Bio Company Profile
(
Get Free Report)
Adicet Bio, Inc, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Adicet Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adicet Bio wasn't on the list.
While Adicet Bio currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
